Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)

NCT03975647 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT03975647
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03975647 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Subjects With Unresectable Locally-advanced or Metastatic HER2+ Breast Cancer (HER2CLIMB-02)
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 2, 2019
Completion date
March 10, 2029
Enrollment
466 (actual)
Sites
490

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer